Santhera sags on FDA delay for Raxone

Santhera Pharmaceuticals Holding AG (SIX:SANN) sank CHF30.85 (37%) to CHF52.65 on Thursday after it said FDA would not support its plan to submit an

Read the full 240 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE